1373 studies found for:    "multiple sclerosis"
Show Display Options
Rank Status Study
21 Not yet recruiting A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis
Conditions: Secondary Progress Multiple Sclerosis;   Multiple Sclerosis
Interventions: Biological: NeuroVax;   Biological: IFA Placebo
22 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
23 Withdrawn Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Relapsing Forms of Multiple Sclerosis
Interventions: Drug: dimethyl fumarate;   Drug: Placebo
24 Temporarily not available Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
Conditions: Multiple Sclerosis;   Autoimmune Diseases;   Disseminated or Multiple Sclerosis Nos;   Multiple Sclerosis, Acute Relapsing;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Tetracycline - Statin - Antimycotic
25 Completed Bayer/Cognitive Assessments With Multiple Sclerosis Subjects
Conditions: Multiple Sclerosis, Relapsing-remitting;   Multiple Sclerosis, Secondary Progressive
Intervention:
26 Completed Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive
Intervention: Biological: Tovaxin Autologous T Cell Vaccine
27 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
28 Completed Safety of RG2077 in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: RG2077 (CTLA4-IgG4m)
29 Active, not recruiting Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
30 Active, not recruiting Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Conditions: Autoimmune Diseases of the Nervous System;   Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Disease Progression;   Brain Atrophy
Interventions: Biological: Tcelna;   Biological: Placebo
31 Completed
Has Results
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
32 Completed
Has Results
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: natalizumab
33 Withdrawn Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
34 Active, not recruiting An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: dimethyl fumarate
35 Completed Treatment of Multiple Sclerosis Using Over the Counter Inosine
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Inosine
36 Completed A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
37 Active, not recruiting Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: BIIB019 (Daclizumab)
38 Recruiting Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
Conditions: Progressive Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Other: Neuropsychological assessment;   Other: Neurologic consultation;   Other: MRIs (with vasoreactivity testing)
39 Completed High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
Conditions: Multiple Sclerosis (MS);   Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Granulocyte-colony stimulating factor (G-CSF) and prednisone;   Drug: Carmustine, etoposide, cytarabine, and melphalan (BEAM);   Procedure: Autologous hematopoietic stem cell transplant
40 Active, not recruiting Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive
Interventions: Drug: ibudilast;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years